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Summary. Malignant tumors are characterized by their 
great heterogeneity and variability. There are hundreds 
of different types of malignant tumors that harbour many 
oncogenic alterations. The tumor heterogeneity has 
important morphological, molecular and clinical 
implications. Except for some hematopoietic and 
lymphoproliferative processes and small cell infant 
tumors, there are not specific molecular alterations for 
most human tumors. In this review we summarize the 
most important aspects of carcinogenesis and chemo- 
radiosensitivity of malignant cells. In this regard, some 
oncogenes such as neu, ras and bcl-2 have been 
associated with cellular resistance to treatment with 
anticancer agents. The knowledge of oncogenic 
alterations involved in each tumor can be important to 
correlate the morphological features, the genetic 
background, the prognosis and the clinical response to 
treatment with anticancer agents. Based on the molecular 
background of the tumor there are new cancer gene 
therapy protocols. For example using adenovirus Ela in 
tumors with overexpression of neu oncogene, inhibitors 
of tirosine kinase specific for the PDGF receptor in 
glioma, inhibitors of farnesil transferase to prevent ras 
activity in tumors with mutations in the ras gene. 
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1. Introduction 
Malignant tumors constitute the second greatest 
cause of mortality in western countries, with more than 
500,000 deaths per year attributable to cancer in the US 
in 1991 (Mcginnis and Foege, 1993; Arnes et al., 1995; 
Byers et al., 1999). Breast, colon, prostate, and lung 
tumors together were responsible for more than 50% of 
those deaths (Callahan et al., 1992; Aaltonen et al., 
1993; Mcginnis and Foege, 1993). 
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During the last 15 years the incidence of a number of 
different tumor types, especially prostate carcinoma, 
melanoma, hepatocellular carcinoma, and non-Hodgkins 
lymphoma, has risen. During the same period, an 
increase of around 15% in the rate of breast cancer has 
been observed, along with a steady rate of colon cancer. 
Correspondingly, the death-rate in the majority of the 
above-mentioned tumor groups has been on the rise. 
It is estimated that in developed countries, 
approximately one third of the population will develop 
cancer at some time in their life. However the probability 
of contracting a specific type of cancer depends on many 
variables, among which should be mentioned: sex, age, 
geography, exposure to carcinogens and genetic 
predisposition. 
Human tumor formation is a complex process which 
requires the accumulation of multiple oncogenic 
alterations. These alterations are associated with the 
development of tumors showing a histopathological 
progression from incipient lesions to carcinomas. 
Malignant cell transformation is related to the activation 
of several oncogenes and the inactivation of several 
tumor suppressor genes. In this process, cells fail to 
differentiate and regulate the cell cycle (Ramon y Cajal, 
1997). 
  here is great heterogeneity and variability among 
human tumors (more than 250 types). The fact that some 
authors have encountered different spectrums of genetic 
alterations in primary tumors and their metastases is the 
result of intratumoral heterogeneity leading to 
dissemination in only some sub-clones (Zborovskaya et 
al., 1999). Also, evidence of intratumoral heterogeneity 
has been described by some authors in relation to DNA 
content (Ruiz-Cerda et al., 1999). 
The development of molecular biology techniques 
has contributed considerably to a wider knowledge of 
oncogenes and tumor suppressor genes (Van der Luijt et 
al., 1994; Lleonart et al., 1997; Laken et al., 1998) 
Recently, the discovery of oncogenes has opened the 
way to a molecular approach to cancer, with more than 
80 oncogenes described up to now, and more than 20 
suppressor genes, whose deletion or mutation can be of 
great importance in tumor development (Bishop, 1991; 

















